Clinician-Scientist | Fujian Medical University | China
Dr. Shenglin Wang is a biomedical researcher whose work focuses on tumor biology, cancer metastasis, and molecular mechanisms underlying osteosarcoma, chondrosarcoma, and lung cancer bone lesions. He completed a Post-doctoral Fellowship at Fujian Medical University where he advanced single-cell sequencing, tumor microenvironment profiling, and molecular pathology research. In 2025, he joined The First Affiliated Hospital of Fujian Medical University as a Physician, continuing to integrate clinical oncology with translational cancer research.Over the last five years, Dr. Wang has secured three competitive research grants as Principal Investigator or Co-Investigator. His ongoing NSFC project investigates SOX18-mediated endothelial senescence and HBEGF secretion in non-small cell lung cancer bone metastasis, aiming to define novel therapeutic targets within the senescent vascular niche. He also leads a provincial project exploring HMGA2-regulated ferroptosis resistance in chondrosarcoma, contributing to the understanding of tumor progression and cell death mechanisms. His completed NSFC project, focused on aptamer-based electrochemical sensing for rapid detection of circulating tumor cells, reflects his multidisciplinary approach combining bioengineering with oncology.Dr. Wang has authored 33 peer-reviewed publications, accumulating 651 citations, with an h-index of 11, demonstrating sustained research productivity and academic impact. His representative articles include studies in Cell Proliferation, Frontiers in Immunology, and Acta Biochimica et Biophysica Sinica, covering topics such as single-cell transcriptomics of metastatic bone microenvironments, immune regulatory networks in thyroid carcinoma, and STAT3/EGFR signaling in osteosarcoma drug resistance. His collaborative work spans more than 60 co-authors, highlighting strong interdisciplinary engagement.Collectively, Dr. Wang’s research advances understanding of tumor microenvironment remodeling, therapeutic resistance, and metastasis-associated cell senescence. His contributions support the development of precision oncology strategies and have broad implications for improving diagnostic, prognostic, and therapeutic outcomes in bone-related malignancies.
Featured Publications
1. Author(s). (2025). The integrin α2–osteoclast axis: A key driver of bone destruction and therapeutic target in osteosarcoma. Journal of Translational Medicine.
2. Author(s). (2021). Corrigendum: Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway. Acta Biochimica et Biophysica Sinica, 53(12), 1670–1680.
3. Author(s). (2025). Single-cell transcriptomic analysis of the senescent microenvironment in bone metastasis. Cell Proliferation, 58(1), e13743. Cited By : 5
The nominee’s work advances precision oncology by uncovering key molecular and microenvironmental mechanisms that drive tumor progression, therapeutic resistance, and bone metastasis, enabling the development of more effective diagnostic and therapeutic strategies. By integrating single-cell analytics, molecular signaling research, and translational innovation, the nominee contributes to improved cancer outcomes and supports global efforts toward personalized, mechanism-driven cancer care.